For how we live.
A CMS and CDC proposed rule would codify pandemic-era remote review of digital lab data, allow digital images in gynaecologic cytology proficiency testing, and ease 2024 staffing rules. Comments close 7 December.
In a Canadian cohort of 228 women with HIV, antibody titres matched those of women without HIV and cervical precancer was not recorded — but protection tracked with viral suppression.
An IARC worldwide incidence analysis puts the infection-attributable share at 12%, led by H pylori and HPV, with eastern Asia carrying the heaviest load and most of the toll preventable.
For the HPV tests now used in primary screening, a self-collected vaginal sample is about as accurate as one a clinician takes — and mailing kits to under-screened women roughly doubles uptake.
The Women's Preventive Services Initiative now endorses patient-collected HPV tests for average-risk women aged 30 to 65. HRSA has adopted the update for no-cost insurance coverage from 2027.
Two 2026 studies posted high accuracy for AI reading Pap-smear cells and colposcopy images in settings short of pathologists. Both were validated internally, which is where such numbers usually shrink.
US guidelines now let women aged 30 to 65 screen every five years with an HPV test. One major body would make that the primary test from age 25 — and self-collected samples work about as well.
Two national studies settle the question the trials could not: in England, cancer rates fell 87% among those vaccinated at 12-13; in Sweden, the risk was cut by nearly two-thirds.
Pooling the trials, one- and two-dose HPV schedules produced lower antibody titres than three doses but still cut persistent infection — with the usual caveat about surrogate endpoints.
A 398-caregiver study across all five island groups finds the single biggest predictor of HPV vaccination was knowing the vaccine was free — after a decade of the programme running.
IARC and WHO put five modules on screening and precancer management online. The 90-70-90 targets they support depend on health workers who can act on a positive test.
VENUSCANCER assembled individual records for 275,792 women from 103 cancer registries in 39 countries. The gaps it found are in what treatment women actually received, not only in whether they were diagnosed.